COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC), ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA

被引：0

作者：

Saggia, M. G. ^{[1
]}

Nasciben, V. D. ^{[2
]}

Santos, E. V. ^{[1
]}

机构：

[1] Roche Pharmaceut, Hlth Econ, Sao Paulo, Brazil

[2] Prod Roche Quim & Farmaceut, Hlth Econ, Sao Paulo, Brazil

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：148 / 148

页数：1

共 50 条

[1] COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN BRAZIL
Saggia, M. G.
Nasciben, V. D.
Santos, E. A.
Stefani, S.
VALUE IN HEALTH, 2008, 11 (06) : A474 - A474
[2] COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER, ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA
Caponero, R.
Saggia, M. G.
Nasciben, V. D.
ANNALS OF ONCOLOGY, 2008, 19 : 130 - 131
[3] Cost-minimization comparison of infusion based FOLFIRI (5-fluorouracil and leucovorin) versus oral based XELIRI (capecitabine and irinotecan) in metastatic colorectal cancer (mCRC).
Baran, R
McKenna, E
Patt, Y
Ghali, N
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 309S - 309S
[4] COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX ± BEVACIZUMAB FOR TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN SAUDI ARABIAN HOSPITAL SETTING
Zazaa, A. S.
AlOmar, H.
El-Moursy, S. A.
AlFayyadh, M.
VALUE IN HEALTH, 2009, 12 (07) : A278 - A278
[5] COST MINIMIZATION ANALYSIS OF TEGAFUR-URACIL ASSOCIATED TO LEUCOVORIN (UFT/LV) VERSUS CAPECITABINE ALONE FOR METASTATIC COLORECTAL CANCER UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Teich, V. D.
Passos, R. B. F.
Teich, N.
VALUE IN HEALTH, 2009, 12 (07) : A497 - A498
[6] COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS 5-FLUOROURACIL FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER: A DECISION TREE MODEL APROACH
Lau, M. S.
Dusetzina, S. B.
VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
[7] Cost-Minimization Analysis of the Treatment of Patients With Metastatic Colorectal Cancer in Greece
Fragoulakis, Vassilis
Papagiannopoulou, Vasilia
Kourlaba, Georgia
Maniadakis, Nikolaos
Fountzilas, Georgios
CLINICAL THERAPEUTICS, 2012, 34 (10) : 2132 - 2142
[8] Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan
Hsu, Tzu-Chi
Wang, Chi-Chuan
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (02) : 73 - 79
[9] COST-MINIMIZATION ANALYSIS OF XELOX VERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL
Caponero, R.
Saggia, M. G.
Nasciben, V. D.
Santos, E. A.
Stefani, S.
VALUE IN HEALTH, 2008, 11 (06) : A474 - A475
[10] COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FOR THE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA, ACCORDING TO THE RECOMMENDED BRAZILIAN GUIDELINES FOR HTA
Lago, S.
Saggia, M. G.
Nasciben, V. D.
ANNALS OF ONCOLOGY, 2008, 19 : 278 - 279

← 1 2 3 4 5 →